Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials

Nazik Rayman; King H. Lam; Bronno van der Holt; Clara Koss; Dennis Veldhuizen; Leo M. Budel; Andries H. Mulder; Leo F. Verdonck; Ruud Delwel; Daphne de Jong; Gustaaf W. van Imhoff; Pieter Sonneveld

doi:10.3816/CLML.2011.n.003

Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials

Nazik Rayman^*, King H. Lam, Bronno van der Holt, Clara Koss, Dennis Veldhuizen, Leo M. Budel, Andries H. Mulder, Leo F. Verdonck, Ruud Delwel, Daphne de Jong, Gustaaf W. van Imhoff, Pieter Sonneveld

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

Abstract

Purpose: Until now molecular biologic techniques have not been easily used in daily clinical practice to stratify patients for therapeutic purposes. Therefore, we have investigated the prognostic relevance of the immunohistochemical (IHC) germinal center B-cell (GCB) versus non-GCB diffuse large B-cell lymphoma (DLBCL) subtypes. Patient; and Methods: We have analyzed tumor samples from patients treated in 2 prospective multicenter phase III trials, ie HOVON 25 (patients >= 65 years, n = 153) and HOVON 26 (patients

Original language	English
Pages (from-to)	23-32
Number of pages	10
Journal	Clinical lymphoma myeloma & leukemia
Volume	11
Issue number	1
DOIs	https://doi.org/10.3816/CLML.2011.n.003
Publication status	Published - Feb-2011

Keywords

DLBCL
Germinal center B-cell
Immunohistochemistry
NON-HODGKINS-LYMPHOMA
CHEMOTHERAPY PLUS RITUXIMAB
RANDOMIZED CONTROLLED-TRIAL
GERMINAL CENTER PHENOTYPE
ELDERLY-PATIENTS
TISSUE MICROARRAY
RISK STRATIFICATION
PROTEIN EXPRESSION
DISTINCT SUBGROUPS
CD10 EXPRESSION

Access to Document

10.3816/CLML.2011.n.003

Handle.net

Persistent link

Cite this

Rayman, N., Lam, K. H., van der Holt, B., Koss, C., Veldhuizen, D., Budel, L. M., Mulder, A. H., Verdonck, L. F., Delwel, R., de Jong, D., van Imhoff, G. W., & Sonneveld, P. (2011). Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials. Clinical lymphoma myeloma & leukemia, 11(1), 23-32. https://doi.org/10.3816/CLML.2011.n.003

@article{92e79acb0ae8440da542cd604f3d158d,

title = "Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials",

abstract = "Purpose: Until now molecular biologic techniques have not been easily used in daily clinical practice to stratify patients for therapeutic purposes. Therefore, we have investigated the prognostic relevance of the immunohistochemical (IHC) germinal center B-cell (GCB) versus non-GCB diffuse large B-cell lymphoma (DLBCL) subtypes. Patient; and Methods: We have analyzed tumor samples from patients treated in 2 prospective multicenter phase III trials, ie HOVON 25 (patients >= 65 years, n = 153) and HOVON 26 (patients",

keywords = "DLBCL, Germinal center B-cell, Immunohistochemistry, NON-HODGKINS-LYMPHOMA, CHEMOTHERAPY PLUS RITUXIMAB, RANDOMIZED CONTROLLED-TRIAL, GERMINAL CENTER PHENOTYPE, ELDERLY-PATIENTS, TISSUE MICROARRAY, RISK STRATIFICATION, PROTEIN EXPRESSION, DISTINCT SUBGROUPS, CD10 EXPRESSION",

author = "Nazik Rayman and Lam, {King H.} and {van der Holt}, Bronno and Clara Koss and Dennis Veldhuizen and Budel, {Leo M.} and Mulder, {Andries H.} and Verdonck, {Leo F.} and Ruud Delwel and {de Jong}, Daphne and {van Imhoff}, {Gustaaf W.} and Pieter Sonneveld",

year = "2011",

month = feb,

doi = "10.3816/CLML.2011.n.003",

language = "English",

volume = "11",

pages = "23--32",

journal = "Clinical lymphoma myeloma & leukemia",

issn = "2152-2650",

publisher = "Elsevier",

number = "1",

}

Rayman, N, Lam, KH, van der Holt, B, Koss, C, Veldhuizen, D, Budel, LM, Mulder, AH, Verdonck, LF, Delwel, R, de Jong, D, van Imhoff, GW & Sonneveld, P 2011, 'Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials', Clinical lymphoma myeloma & leukemia, vol. 11, no. 1, pp. 23-32. https://doi.org/10.3816/CLML.2011.n.003

TY - JOUR

T1 - Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials

AU - Rayman, Nazik

AU - Lam, King H.

AU - van der Holt, Bronno

AU - Koss, Clara

AU - Veldhuizen, Dennis

AU - Budel, Leo M.

AU - Mulder, Andries H.

AU - Verdonck, Leo F.

AU - Delwel, Ruud

AU - de Jong, Daphne

AU - van Imhoff, Gustaaf W.

AU - Sonneveld, Pieter

PY - 2011/2

Y1 - 2011/2

N2 - Purpose: Until now molecular biologic techniques have not been easily used in daily clinical practice to stratify patients for therapeutic purposes. Therefore, we have investigated the prognostic relevance of the immunohistochemical (IHC) germinal center B-cell (GCB) versus non-GCB diffuse large B-cell lymphoma (DLBCL) subtypes. Patient; and Methods: We have analyzed tumor samples from patients treated in 2 prospective multicenter phase III trials, ie HOVON 25 (patients >= 65 years, n = 153) and HOVON 26 (patients

AB - Purpose: Until now molecular biologic techniques have not been easily used in daily clinical practice to stratify patients for therapeutic purposes. Therefore, we have investigated the prognostic relevance of the immunohistochemical (IHC) germinal center B-cell (GCB) versus non-GCB diffuse large B-cell lymphoma (DLBCL) subtypes. Patient; and Methods: We have analyzed tumor samples from patients treated in 2 prospective multicenter phase III trials, ie HOVON 25 (patients >= 65 years, n = 153) and HOVON 26 (patients

KW - DLBCL

KW - Germinal center B-cell

KW - Immunohistochemistry

KW - NON-HODGKINS-LYMPHOMA

KW - CHEMOTHERAPY PLUS RITUXIMAB

KW - RANDOMIZED CONTROLLED-TRIAL

KW - GERMINAL CENTER PHENOTYPE

KW - ELDERLY-PATIENTS

KW - TISSUE MICROARRAY

KW - RISK STRATIFICATION

KW - PROTEIN EXPRESSION

KW - DISTINCT SUBGROUPS

KW - CD10 EXPRESSION

U2 - 10.3816/CLML.2011.n.003

DO - 10.3816/CLML.2011.n.003

M3 - Article

SN - 2152-2650

VL - 11

SP - 23

EP - 32

JO - Clinical lymphoma myeloma & leukemia

JF - Clinical lymphoma myeloma & leukemia

IS - 1

ER -

Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this